Business Wire

MITSUBISHI-HITACHI

Share
MHPS Captures Global Gas Turbine Market Share Leadership Again

Mitsubishi Hitachi Power Systems (MHPS) ranks first in market share by megawatts for gas turbine orders in 2020 according to data obtained from McCoy Power Reports. First quarter global orders of 2,638 MW brought MHPS’ market share to 28.5 percent globally. This increase in gas turbine market share was largely responsible for worldwide order booking increasing 19.7 percent during MHPS’ fiscal year ending March 31, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005485/en/

“The extremely competitive global gas turbine market has moved in our direction with a clear preference for our JAC gas turbines, which are more reliable than competitor’s gas turbines while providing record-setting fuel efficiency and output,” said Ken Kawai, MHPS President and Chief Executive Officer. “Sales of MHPS’ gas turbines in both the advanced class and aero-derivative segments have gained momentum as utilities, independent power producers and municipalities around the world seek to lower their electricity cost through our unique combination of proven reliability and world class performance.”

MHPS’ J-Series gas turbines first entered commercial operation in 2011 and hold world-record reliability at 99.5%. In addition, they deliver combined cycle efficiency greater than 64%. The installed fleet of J-Series gas turbines recently achieved one million hours of commercial operation worldwide, which is nearly double that of competitors’ similar sized gas turbines.

Boosting MHPS’ first quarter 2020 market share was an order for the first two renewable-hydrogen-capable JAC gas turbines for the Intermountain Power Agency in Delta, Utah. Dan Eldredge of the Intermountain Power Agency said, "We chose MHPS' JAC power trains because they offered the best overall solution for our power generation equipment requirements, including the fuel flexibility that will enable us to meet our incremental goals toward 100% carbon-free power generation by 2045. With MHPS' tools and support, we expect to reliably provide cleaner power for decades to come."

Forty-five J-Series gas turbines are in commercial operation, and total ordered capacity exceeds 25 GW globally. One hundred and four units have been technically selected in Brazil, Canada, Japan, Mexico, Peru, South Korea, Taiwan, Thailand, and the United States.

“The marketplace has recognized our efforts through a wave of technical selections and orders placed,” said Junichiro Masada, Senior Vice President, Co-Chief Technology Officer, and Deputy Head of Turbomachinery Headquarters, MHPS. “And we continue to improve our technology. For example, we recently synced to the grid in Takasago, Japan, and reached full load with the latest 60 Hz enhancement of the JAC, demonstrating record-setting output and combined cycle efficiency. Competitors are years away from entering operation with a gas turbine of this size or efficiency. In addition, we recently demonstrated a significant performance enhancement of the FT4000 at our test facility in West Palm Beach, Florida.”

The FT4000 aero-derivative gas turbine, with multiple active projects in North America and internationally, has tripled its global footprint in the past two years and captured significant market share in its class since the purchase of PW Power Systems (PWPS) in 2013. The PWPS FT4000 first entered commercial operation in 2015 and delivers industry-leading simple cycle efficiency, start time and ramp rate.

“We are proud that our technology has launched us to global leadership in the competitive gas turbine market,” said Ken Kawai, President and Chief Executive Officer. “We value the contributions of our employees around the world who are focused on bringing advanced technologies and energy solutions to the marketplace for affordable and reliable power supplies. We remain committed to enabling a decarbonized economy and helping to resolve the challenges facing our global society.”

About Mitsubishi Hitachi Power Systems, Ltd.

Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS recently announced that its name will soon change to Mitsubishi Power. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com .

Follow us at
https://twitter.com/MHPS_Global , or http://www.linkedin.com/showcase/mhps

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Acquires Alliance Ground International22.1.2026 14:55:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire Alliance Ground International (“AGI”), a leading North American airport services provider, from Greenbriar Equity Group and Audax Private Equity. Financial terms of the transaction were not disclosed. Founded in 1987 and headquartered in Miami, AGI operates in over 60 airports in North America with a workforce of more than 12,000 professionals. The company provides mission-critical, outsourced services that enable the efficient movement of cargo and passenger aircraft through major airport hubs. AGI’s core business is air cargo handling, supported by passenger terminal, ground handling and other related services. Its integrated service offering, strategic on-airport footprint and long-standing customer relationships position AGI as a trusted partner to cargo carriers and passenger airlines, supporting airport operations and global trade flows. L

Andersen Consulting konsoliderer sit udbud inden for digital transformation med tilføjelsen af Internet & Idee22.1.2026 14:04:00 CET | Pressemeddelelse

Andersen Consulting indgår en samarbejdsaftale med Internet & Idee, et italiensk digitalt konsulentbureau, og styrker dermed sin evne til at levere integrerede, teknologidrevne løsninger. Internet & Idee blev stiftet i 1998 og specialiserer sig i digital strategi, softwareudvikling, test og kvalitetssikring, e-handel og mobile løsninger. Virksomheden opererer inden for to kerneområder: It-konsulentydelser og egne SaaS-produkter, herunder værktøjer til kreditstyring og cybersikkerhed. Med dyb ekspertise inden for bankvæsen, forsikring, kreditstyring og logistik for e-handel kombinerer Internet & Idee brancheindsigt med teknisk innovation med henblik på at drive forretningsresultater. "Dette samarbejde giver os mulighed for at anvende vores digitale ekspertise og branchekendskab i større skala," udtaler Carlo Stumpo, administrerende direktør for Internet & Idee. "Sammen med Andersen Consulting kan vi levere mere målrettede og effektive løsninger til kunder, der står over for komplekse ud

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer22.1.2026 14:00:00 CET | Press release

Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant’s New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026 Relacorilant’s Marketing Authorization Application (MAA) for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA) Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitax

ExaGrid Announces All Flash/SSD Tiered Backup Storage Solution22.1.2026 14:00:00 CET | Press release

ExaGrid’s new solution offers the fastest, most scalable, and most secure backups in the industry ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it is shipping an All Flash/SSD backup storage solution with a unique front-end Landing Zone and non-network-facing Repository Tier (tiered air gap) that stores all backup retention using advanced data deduplication. The new SSD appliances ship with ExaGrid software version 8. ExaGrid’s unique Landing Zone and scale-out architecture allow for significantly faster backups and restores, as well as scalability as data grows, versus other SSD products such as Dell Data Domain inline deduplication appliances with SSD or straight SSD from Pure Storage. Due to three years of software work and the extremely fast performance of SSD, ExaGrid’s

Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis22.1.2026 14:00:00 CET | Press release

New Trailmaker functionality integrates immune repertoire and whole transcriptome data to deliver rapid, publication-ready insights Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker™. The new functionality complements Parse’s existing portfolio of Evercode immune products to enable a full end-to-end workflow for researchers. Immunologists have lacked an integrated, purpose-built platform capable of connecting immune repertoire data with whole transcriptome single cell insights. As a result, interpreting clonal behavior, understanding functional cell states, and drawing meaningful biological conclusions has often required stitching together fragmented tools, custom code, or inconsistent visualization approaches. The new Trailmaker functionality directly addresses these challenges by provi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye